J Doescher1, S Jeske1, S E Weissinger2, C Brunner1, S Laban1, E Bölke3, T K Hoffmann1, T L Whiteside4, P J Schuler5. 1. Department of Otolaryngology, Head and Neck Surgery, University of Ulm, Frauensteige 12, 89075, Ulm, Germany. 2. Department of Pathology, University of Ulm, Ulm, Germany. 3. Department for Radiotherapy and Radiooncology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany. 4. University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, USA. 5. Department of Otolaryngology, Head and Neck Surgery, University of Ulm, Frauensteige 12, 89075, Ulm, Germany. patrick.schuler@uniklinik-ulm.de.
Abstract
BACKGROUND: For head and neck squamous cell cancer (HNSCC), standard therapy consists of surgery, radiation, and/or chemotherapy. Antineoplastic immunotherapy could be an option in an adjuvant setting and is already in palliation. A functional immune system is a prerequisite for successful immunotherapy. However, effects of the standard-of-care therapy on the patients' immune system are not fully understood. METHODS: Peripheral blood mononuclear cells (PBMC) were collected from patients with HNSCC (n = 37) and healthy controls (n = 10). PBMC were stimulated with staphylococcal enterotoxin B (SEB). Simultaneous expression of various cytokines was measured in CD4+ and CD8+ T cells by multicolor flow cytometry, and polyfunctional cytokine expression profiles were determined on a single-cell basis. RESULTS: Expression levels of all measured cytokines in CD4+ T cells were higher in patients after chemoradiotherapy (CRT) as compared to untreated HNSCC patients or normal controls. After CRT, the frequency of polyfunctional CD4+ T cells, which simultaneously expressed multiple cytokines, was significantly increased as compared to untreated patients (p < 0.01). CONCLUSION: CRT increases polyfunctionality of CD4+ T cells in HNSCC patients, suggesting that standard-of-care therapy can promote immune activity in immune cells. These polyfunctional CD4+ T cells in the blood of treated HNSCC patients are expected to be responsive to subsequent immunotherapeutic approaches.
BACKGROUND: For head and neck squamous cell cancer (HNSCC), standard therapy consists of surgery, radiation, and/or chemotherapy. Antineoplastic immunotherapy could be an option in an adjuvant setting and is already in palliation. A functional immune system is a prerequisite for successful immunotherapy. However, effects of the standard-of-care therapy on the patients' immune system are not fully understood. METHODS: Peripheral blood mononuclear cells (PBMC) were collected from patients with HNSCC (n = 37) and healthy controls (n = 10). PBMC were stimulated with staphylococcal enterotoxin B (SEB). Simultaneous expression of various cytokines was measured in CD4+ and CD8+ T cells by multicolor flow cytometry, and polyfunctional cytokine expression profiles were determined on a single-cell basis. RESULTS: Expression levels of all measured cytokines in CD4+ T cells were higher in patients after chemoradiotherapy (CRT) as compared to untreated HNSCC patients or normal controls. After CRT, the frequency of polyfunctional CD4+ T cells, which simultaneously expressed multiple cytokines, was significantly increased as compared to untreated patients (p < 0.01). CONCLUSION: CRT increases polyfunctionality of CD4+ T cells in HNSCC patients, suggesting that standard-of-care therapy can promote immune activity in immune cells. These polyfunctional CD4+ T cells in the blood of treated HNSCC patients are expected to be responsive to subsequent immunotherapeutic approaches.
Authors: Thomas K Hoffmann; Eniko Sonkoly; Bernhard Homey; Katrin Scheckenbach; Christian Gwosdz; Murat Bas; Adam Chaker; Kerstin Schirlau; Theresa L Whiteside Journal: Head Neck Date: 2007-05 Impact factor: 3.147
Authors: John R Yannelli; Jo A Tucker; Giovanna Hidalgo; Sara Perkins; Richard Kryscio; Edward A Hirschowitz Journal: Oncol Rep Date: 2009-12 Impact factor: 3.906
Authors: Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Zenichiro Saze; Laura Strauss; Stephan Lang; Jonas T Johnson; Theresa L Whiteside Journal: Clin Cancer Res Date: 2013-10-04 Impact factor: 12.531
Authors: Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup Journal: Blood Date: 2006-02-07 Impact factor: 22.113
Authors: Patrick J Schuler; Bastian Schilling; Malgorzata Harasymczuk; Thomas K Hoffmann; Jonas Johnson; Stephan Lang; Theresa L Whiteside Journal: Eur J Immunol Date: 2012-06-18 Impact factor: 5.532